These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21910132)

  • 1. A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites.
    Nagarajan M; Maruthanayagam V; Sundararaman M
    J Appl Toxicol; 2012 Mar; 32(3):153-85. PubMed ID: 21910132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR analysis and bioactive potentials of freshwater and terrestrial cyanobacterial compounds: a review.
    Nagarajan M; Maruthanayagam V; Sundararaman M
    J Appl Toxicol; 2013 May; 33(5):313-49. PubMed ID: 23172644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical agents from filamentous marine cyanobacteria.
    Tan LT
    Drug Discov Today; 2013 Sep; 18(17-18):863-71. PubMed ID: 23711931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactive natural products from marine cyanobacteria for drug discovery.
    Tan LT
    Phytochemistry; 2007 Apr; 68(7):954-79. PubMed ID: 17336349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxic cyanobacterial toxins.
    Aráoz R; Molgó J; Tandeau de Marsac N
    Toxicon; 2010 Oct; 56(5):813-28. PubMed ID: 19660486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecotoxicological effects of selected cyanobacterial secondary metabolites: a short review.
    Wiegand C; Pflugmacher S
    Toxicol Appl Pharmacol; 2005 Mar; 203(3):201-18. PubMed ID: 15737675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marine cyanobacteria compounds with anticancer properties: a review on the implication of apoptosis.
    Costa M; Costa-Rodrigues J; Fernandes MH; Barros P; Vasconcelos V; Martins R
    Mar Drugs; 2012 Oct; 10(10):2181-2207. PubMed ID: 23170077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifouling potential of cyanobacteria: a mini-review.
    Dahms HU; Ying X; Pfeiffer C
    Biofouling; 2006; 22(5-6):317-27. PubMed ID: 17110355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in therapeutic applications of Cyanobacteria.
    Raja R; Hemaiswarya S; Ganesan V; Carvalho IS
    Crit Rev Microbiol; 2016 May; 42(3):394-405. PubMed ID: 25629310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyanobacterial bioactive molecules--an overview of their toxic properties.
    Jaiswal P; Singh PK; Prasanna R
    Can J Microbiol; 2008 Sep; 54(9):701-17. PubMed ID: 18772933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotechnological and industrial significance of cyanobacterial secondary metabolites.
    Rastogi RP; Sinha RP
    Biotechnol Adv; 2009; 27(4):521-39. PubMed ID: 19393308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyanobacterial cyclic lipopeptides puwainaphycins F/G are inducing necrosis via cell membrane permeabilization and subsequent unusual actin relocalization.
    Hrouzek P; Kuzma M; Černý J; Novák P; Fišer R; Simek P; Lukešová A; Kopecký J
    Chem Res Toxicol; 2012 Jun; 25(6):1203-11. PubMed ID: 22551534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring marine cyanobacteria for lead compounds of pharmaceutical importance.
    Uzair B; Tabassum S; Rasheed M; Rehman SF
    ScientificWorldJournal; 2012; 2012():179782. PubMed ID: 22545008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of biological activity profiles of cyanobacterial secondary metabolites.
    Devillers J; Doré JC; Guyot M; Poroikov V; Gloriozova T; Lagunin A; Filimonov D
    SAR QSAR Environ Res; 2007; 18(7-8):629-43. PubMed ID: 18038364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary metabolites from marine cyanobacteria and algae inhibit LFA-1/ICAM-1 mediated cell adhesion.
    Takamatsu S; Nagle DG; Gerwick WH
    Planta Med; 2004 Feb; 70(2):127-31. PubMed ID: 14994189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marine pharmacology in 2001-2: antitumour and cytotoxic compounds.
    Mayer AM; Gustafson KR
    Eur J Cancer; 2004 Dec; 40(18):2676-704. PubMed ID: 15571951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyanobacteria derived compounds: Emerging drugs for cancer management.
    Shahid A; Khurshid M; Aslam B; Muzammil S; Mehwish HM; Rajoka MSR; Hayat HF; Sarfraz MH; Razzaq MK; Nisar MA; Waseem M
    J Basic Microbiol; 2022 Sep; 62(9):1125-1142. PubMed ID: 34747529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-ribosomal peptides produced by Brazilian cyanobacterial isolates with antimicrobial activity.
    Silva-Stenico ME; Silva CS; Lorenzi AS; Shishido TK; Etchegaray A; Lira SP; Moraes LA; Fiore MF
    Microbiol Res; 2011 Mar; 166(3):161-75. PubMed ID: 20630723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyanobacterial peptides - nature's own combinatorial biosynthesis.
    Welker M; von Döhren H
    FEMS Microbiol Rev; 2006 Jul; 30(4):530-63. PubMed ID: 16774586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactive secondary metabolites from marine microbes for drug discovery.
    Nikapitiya C
    Adv Food Nutr Res; 2012; 65():363-87. PubMed ID: 22361200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.